南新制药拟公开挂牌转让部分应收账款 优化资产结构提升运营质效

Core Viewpoint - The company, Hunan Nanxin Pharmaceutical Co., Ltd., is planning to transfer part of its accounts receivable through public listing to optimize its asset structure, focus on core business, and enhance risk resistance [1][2]. Group 1: Strategic Initiatives - The public listing of accounts receivable aims to reduce management costs associated with receivables, allowing the company to concentrate resources on core development areas and increase investment in innovative drug research [1]. - This initiative is expected to improve the company's asset structure and operational quality by converting stagnant receivables into cash, thereby reducing the proportion of accounts receivable in total assets and transferring credit risk [1]. Group 2: Financial Implications - The transfer of accounts receivable is anticipated to enhance liquidity and security of funds, providing a quick influx of cash to alleviate pressure from capital occupation and mitigate cash flow issues caused by delayed payments [2]. - The company plans to continue optimizing its accounts receivable management system and strengthen its focus on core business and research innovation to create higher value for investors and contribute to industry development [2].